| Q39157279 | A Review of Myeloablative vs Reduced Intensity/Non-Myeloablative Regimens in Allogeneic Hematopoietic Stem Cell Transplantations |
| Q40855399 | A novel reduced intensity conditioning regimen for patients with high-risk hematological malignancies undergoing allogeneic stem cell transplantation |
| Q53615862 | Addition of low dose total body irradiation to fludarabine melphalan reduced intensity conditioning is feasible, tolerable, and may improve outcomes in patients with high-risk acute myeloid leukaemia and other high risk myeloid malignancies. |
| Q55515367 | Allogeneic Hematopoietic Cell Transplantation for Older Adults with Acute Myeloid Leukemia. |
| Q58554859 | Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients With Acute Myeloid Leukemia |
| Q47135533 | Allogeneic Stem Cell Transplant for Acute Myeloid Leukemia: Evolution of an Effective Strategy in India |
| Q38248427 | Allogeneic hematopoietic cell transplantation for acute myeloid leukemia during first complete remission: a clinical perspective |
| Q41531481 | Allogeneic hematopoietic stem cell transplantation for adult patients with mixed phenotype acute leukemia: results of a matched-pair analysis |
| Q85536716 | Allogeneic hematopoietic stem cell transplantation for poor-risk CLL: dissecting immune-modulating strategies for disease eradication and treatment of relapse |
| Q41200444 | Allogeneic transplantation with myeloablative FluBu4 conditioning improves survival compared to reduced intensity FluBu2 conditioning for acute myeloid leukemia in remission |
| Q40475236 | Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. |
| Q50160436 | CD34+ Cell Selection versus Reduced-Intensity Conditioning and Unmodified Grafts for Allogeneic Hematopoietic Cell Transplantation in Patients Age >50 Years with Acute Myelogenous Leukemia and Myelodysplastic Syndrome . |
| Q98283577 | Cardiovascular outcomes in patients receiving myeloablative vs. reduced intensity conditioning prior to allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia |
| Q33611146 | Characteristics predicting outcomes of allogeneic stem-cell transplantation in relapsed acute myelogenous leukemia |
| Q33689153 | Clinical implications of HLA locus mismatching in unrelated donor hematopoietic cell transplantation: a meta-analysis |
| Q37429911 | Clofarabine versus fludarabine-based reduced-intensity conditioning regimen prior to allogeneic transplantation in adults with AML/MDS. |
| Q53001093 | Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40-60 years. |
| Q64983620 | Comparison of Myeloablative Versus Reduced-Intensity Conditioning Regimens for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia: A Cohort Study |
| Q34360641 | Comparison of reduced-intensity and myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and acute lymphoblastic leukemia: a meta-analysis |
| Q92451380 | Conditioning intensity and antilymphocyte globulin: towards personalized transplant strategies? |
| Q39306717 | Conditioning regimens for allogeneic hematopoietic stem cell transplants in acute myeloid leukemia |
| Q88945356 | Current status and future clinical directions in the prevention and treatment of relapse following hematopoietic transplantation for acute myeloid and lymphoblastic leukemia |
| Q45233774 | Cytogenetic risk grouping by the monosomal karyotype classification is superior in predicting the outcome of acute myeloid leukemia undergoing allogeneic stem cell transplantation in complete remission |
| Q47353129 | Distinct factors determine the kinetics of disease relapse in adults transplanted for acute myeloid leukaemia. |
| Q30408294 | Effect of postremission therapy before reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia in first complete remission |
| Q58814184 | Equivalent outcomes using reduced intensity or conventional myeloablative conditioning transplantation for patients aged 35 years and over with AML |
| Q87445742 | Expanding transplant options to patients over 50 years. Improved outcome after reduced intensity conditioning mismatched-unrelated donor transplantation for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the |
| Q90079683 | FLAMSA-RIC for Stem Cell Transplantation in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes: A Systematic Review and Meta-Analysis |
| Q58565569 | Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial |
| Q39677427 | Healthcare Burden, Risk Factors, and Outcomes of Mucosal Barrier Injury Laboratory-Confirmed Bloodstream Infections after Stem Cell Transplantation |
| Q58719438 | Hematopoietic cell transplant for acute myeloid leukemia and myelodysplastic syndrome: conditioning regimen intensity |
| Q51031888 | Hematopoietic cell transplantation in patients with intermediate and high-risk AML: results from the randomized Study Alliance Leukemia (SAL) AML 2003 trial. |
| Q38130168 | Hematopoietic stem cell transplantation for acute myeloid leukemia: to whom, when, and how. |
| Q36687119 | Impact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: a report from the acute leukemia working party of the EBMT. |
| Q90941467 | Impact of conditioning intensity on outcomes of haploidentical stem cell transplantation for patients with acute myeloid leukemia 45 years of age and over |
| Q39651929 | In-vivo dosimetry with Gafchromic films for multi-isocentric VMAT irradiation of total marrow lymph-nodes: a feasibility study |
| Q91855553 | Incorporating posttransplant cyclophosphamide-based prophylaxis as standard-of-care outside the haploidentical setting: challenges and review of the literature |
| Q38387292 | Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015. |
| Q41655945 | Initial fluconazole prophylaxis may not be required in adults with acute leukemia or myelodysplastic/myeloproliferative disorders after reduced intensity conditioning peripheral blood stem cell allogeneic transplantation |
| Q84948796 | Intensity of conditioning for allogeneic haemopoetic cell transplantation |
| Q30884173 | Interpreting outcome data in hematopoietic cell transplantation for leukemia: tackling common biases. |
| Q88088400 | Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised |
| Q90590385 | Long-term results of reduced-intensity conditioning allogeneic hematopoietic cell transplantation for older patients with acute myeloid leukemia: a retrospective analysis of 10-year follow-up data |
| Q44355415 | Long-term survival after allogeneic haematopoietic cell transplantation for AML in remission: single-centre results after TBI-based myeloablative and non-myeloablative conditioning |
| Q59470924 | Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party o |
| Q38852431 | Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes |
| Q90826204 | Myeloablative and reduced-intensity conditioning in HLA-haploidentical peripheral blood stem cell transplantation using post-transplant cyclophosphamide |
| Q90465658 | Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancy |
| Q58554191 | Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia |
| Q92707683 | Nonmyeloablative TLI-ATG conditioning for allogeneic transplantation: mature follow-up from a large single-center cohort |
| Q40438036 | Outcomes of allogeneic stem cell transplantation among patients with acute myeloid leukemia presenting active disease: Experience of a single European Comprehensive Cancer Center |
| Q36117062 | Patients with Acute Myeloid Leukemia Admitted to Intensive Care Units: Outcome Analysis and Risk Prediction |
| Q64122847 | Patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation: trends in survival during the past two decades |
| Q98471396 | Predicting non-relapse mortality following allogeneic hematopoietic cell transplantation during first remission of acute myeloid leukemia |
| Q37270982 | Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia |
| Q38488058 | Pushing the envelope-nonmyeloablative and reduced intensity preparative regimens for allogeneic hematopoietic transplantation |
| Q93040013 | Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients |
| Q40129891 | Reduced BUCY 2 and G-CSF-primed bone marrow associates with low graft-versus-host-disease and transplant-related mortality in allogeneic HSCT. |
| Q35800814 | Reduced intensity conditioning allogeneic hematopoietic cell transplantation for adult acute myeloid leukemia in complete remission - a review from the Acute Leukemia Working Party of the EBMT. |
| Q34075082 | Reduced-intensity allogeneic transplantation using alemtuzumab from HLA-matched related, unrelated, or haploidentical related donors for patients with hematologic malignancies |
| Q34770016 | Reduced-intensity and myeloablative conditioning allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and myelodysplastic syndrome: a meta-analysis and systematic review |
| Q38366632 | Reduced-intensity conditioned allogeneic SCT in adults with AML. |
| Q39005630 | Reduced-intensity conditioning allogeneic hematopoietic cell transplantation for younger patients with acute myeloid leukemia: a registry-based study |
| Q38863489 | Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT. |
| Q26771438 | Risk factors for relapse after allogeneic transplantation in acute myeloid leukemia |
| Q92451784 | Role of alternative donor allogeneic hematopoietic stem cell transplantation in patients with intermediate- or poor-risk acute myeloid leukemia in first complete remission |
| Q34325244 | Second solid cancers after allogeneic hematopoietic cell transplantation using reduced-intensity conditioning |
| Q58776887 | The complexity of stem cell transplants: can we improve our understanding? |
| Q89297777 | The impact of individual comorbidities on non-relapse mortality following allogeneic hematopoietic stem cell transplantation |
| Q30316611 | The indications for allogeneic stem cell transplantation in myeloid malignancies |
| Q91859903 | The role of allogeneic stem cell transplantation in the management of acute myeloid leukaemia: a triumph of hope and experience |
| Q99202596 | Total body irradiation + fludarabine compared to busulfan + fludarabine as "reduced-toxicity conditioning" for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by th |
| Q41564670 | Treatment strategies in patients with AML or high-risk myelodysplastic syndrome relapsed after Allo-SCT. |
| Q91341158 | Unmanipulated haploidentical versus HLA-matched sibling allogeneic hematopoietic stem cell transplantation in relapsed/refractory acute myeloid leukemia: a retrospective study on behalf of the ALWP of the EBMT |